MASLD replaced NAFLD, the former umbrella term for non-alcoholic fatty liver disease in June 2023.
Metabolic-associated steatohepatitis (MASH) is a condition that causes inflammation and liver cell damage, which is often associated with the accumulation of fat in the liver.
In contrast to simple fatty liver, it can develop into more severe conditions including cirrhosis and liver cancer.
The American Journal of Gastroenterology publication, analysed 5,745 adult patients in the cohort from 47 academic and 18 community practice centres in the US.
Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Image credit: Shutterstock/Peakstock
Analytics firm Target RWE has published its findings that 99% of participants in TARGET-NASH, a research registry of patients with nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH) within academic and community real-world practices, meet the new metabolic dysfunction-associated steatotic liver disease (MASLD) diagnostic criteria.
MASLD replaced NAFLD, the former umbrella term for non-alcoholic fatty liver disease in June 2023.
The American Association of Liver Diseases was among the groups that were part of the Nomenclature Development Initiative, which was focused on ensuring the global community had better nomenclature that could be used around the world so that the research and funding could be better directed to save more people’s lives.
Metabolic-associated steatohepatitis (MASH) is a condition that causes inflammation and liver cell damage, which is often associated with the accumulation of fat in the liver. In contrast to simple fatty liver, it can develop into more severe conditions including cirrhosis and liver cancer. Last year, MASH also replaced the term NASH.
The American Journal of Gastroenterology publication, analysed 5,745 adult patients in the cohort from 47 academic and 18 community practice centres in the US.
“Our findings validate the accuracy and relevance of the TARGET-NASH cohort definitions,” said A. Sidney Barritt IV, professor of medicine, director of hepatology, and transplant hepatology program director at the University of North Carolina School of Medicine, Chapel Hill.
How well do you really know your competitors? Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge. View profiles in store Company Profile – free sample Thank you! Your download email will arrive shortly Not ready to buy yet? Download a free sample We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form By GlobalData Submit Country * UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo Industry * Academia & Education Aerospace, Defense & Security Agriculture Asset Management Automotive Banking & Payments Chemicals Construction Consumer Foodservice Government, trade bodies and NGOs Health & Fitness Hospitals & Healthcare HR, Staffing & Recruitment Insurance Investment Banking Legal Services Management Consulting Marketing & Advertising Media & Publishing Medical Devices Mining Oil & Gas Packaging Pharmaceuticals Power & Utilities Private Equity Real Estate Retail Sport Technology Telecom Transportation & Logistics Travel, Tourism & Hospitality Venture Capital Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology. Submit and download Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“The liver community can be assured that the adoption of the MASLD nomenclature will not disrupt ongoing research on disease natural history, biomarker development, or therapeutic interventions for patients originally classified under the legacy definitions for MASL, MASH and MASH cirrhosis from TARGET-NASH.”
Boehringer Ingelheim and Zealand Pharma recently published data from its Phase II trial (NCT04771273) sub-analysis which showed that its GLP-1/glucagon receptor dual agonist survodutide has significantly improved liver fibrosis in patients with MASH.
